Placental extracellular vesicles-associated microRNA-519c mediates endotoxin adaptation in pregnancy.
endotoxin tolerance
extracellular vesicles
inflammation
microRNA
preterm birth
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
15
02
2021
revised:
11
06
2021
accepted:
14
06
2021
pubmed:
29
6
2021
medline:
18
12
2021
entrez:
28
6
2021
Statut:
ppublish
Résumé
Pregnancy represents a unique challenge for the maternal-fetal immune interface, requiring a balance between immunosuppression, which is essential for the maintenance of a semiallogeneic fetus, and proinflammatory host defense to protect the maternal-fetal interface from invading organisms. Adaptation to repeated inflammatory stimuli (endotoxin tolerance) may be critical in preventing inflammation-induced preterm birth caused by exaggerated maternal inflammatory responses to mild or moderate infections that are common during pregnancy. However, the exact mechanisms contributing to the maintenance of tolerance to repeated infections are not completely understood. MicroRNAs play important roles in pregnancy with several microRNAs implicated in gestational tissue function and in pathologic pregnancy conditions. MicroRNA-519c, a member of the chromosome 19 microRNA cluster, is a human-specific microRNA mainly expressed in the placenta. However, its role in pregnancy is largely unknown. This study aimed to explore the role of "endotoxin tolerance" failure in the pathogenesis of an exaggerated inflammatory response often seen in inflammation-mediated preterm birth. In this study, we investigated the role of microRNA-519c, a placenta-specific microRNA, as a key regulator of endotoxin tolerance at the maternal-fetal interface. Using a placental explant culture system, samples from term and second-trimester placentas were treated with lipopolysaccharide. After 24 hours, the conditioned media were collected for analysis, and the placental explants were re-exposed to repeated doses of lipopolysaccharide for 3 days. The supernatant was analyzed for inflammatory markers, the presence of extracellular vesicles, and microRNAs. To study the possible mechanism of action of the microRNAs, we evaluated the phosphodiesterase 3B pathway involved in tumor necrosis factor alpha production using a microRNA mimic and phosphodiesterase 3B small interfering RNA transfection. Finally, we analyzed human placental samples from different gestational ages and from women affected by inflammation-associated pregnancies. Our data showed that repeated exposure of the human placenta to endotoxin challenges induced a tolerant phenotype characterized by decreased tumor necrosis factor alpha and up-regulated interleukin-10 levels. This reaction was mediated by the placenta-specific microRNA-519c packaged within placental extracellular vesicles. Lipopolysaccharide treatment increased the extracellular vesicles that were positive for the exosome tetraspanin markers, namely CD9, CD63, and CD81, and secreted primarily by trophoblasts. Primary human trophoblast cells transfected with a microRNA-519c mimic decreased phosphodiesterase 3B, whereas a lack of phosphodiesterase 3B, achieved by small interfering RNA transfection, led to decreased tumor necrosis factor alpha production. These data support the hypothesis that the anti-inflammatory action of microRNA-519c was mediated by a down-regulation of the phosphodiesterase 3B pathway, leading to inhibition of tumor necrosis factor alpha production. Furthermore, human placentas from normal and inflammation-associated pregnancies demonstrated that a decreased placental microRNA-519c level was linked to infection-induced inflammatory pathologies during pregnancy. We identified microRNA-519c, a human placenta-specific microRNA, as a novel regulator of immune adaptation associated with infection-induced preterm birth at the maternal-fetal interface. Our study serves as a basis for future experiments to explore the potential use of microRNA-519c as a biomarker for infection-induced preterm birth.
Sections du résumé
BACKGROUND
Pregnancy represents a unique challenge for the maternal-fetal immune interface, requiring a balance between immunosuppression, which is essential for the maintenance of a semiallogeneic fetus, and proinflammatory host defense to protect the maternal-fetal interface from invading organisms. Adaptation to repeated inflammatory stimuli (endotoxin tolerance) may be critical in preventing inflammation-induced preterm birth caused by exaggerated maternal inflammatory responses to mild or moderate infections that are common during pregnancy. However, the exact mechanisms contributing to the maintenance of tolerance to repeated infections are not completely understood. MicroRNAs play important roles in pregnancy with several microRNAs implicated in gestational tissue function and in pathologic pregnancy conditions. MicroRNA-519c, a member of the chromosome 19 microRNA cluster, is a human-specific microRNA mainly expressed in the placenta. However, its role in pregnancy is largely unknown.
OBJECTIVE
This study aimed to explore the role of "endotoxin tolerance" failure in the pathogenesis of an exaggerated inflammatory response often seen in inflammation-mediated preterm birth. In this study, we investigated the role of microRNA-519c, a placenta-specific microRNA, as a key regulator of endotoxin tolerance at the maternal-fetal interface.
STUDY DESIGN
Using a placental explant culture system, samples from term and second-trimester placentas were treated with lipopolysaccharide. After 24 hours, the conditioned media were collected for analysis, and the placental explants were re-exposed to repeated doses of lipopolysaccharide for 3 days. The supernatant was analyzed for inflammatory markers, the presence of extracellular vesicles, and microRNAs. To study the possible mechanism of action of the microRNAs, we evaluated the phosphodiesterase 3B pathway involved in tumor necrosis factor alpha production using a microRNA mimic and phosphodiesterase 3B small interfering RNA transfection. Finally, we analyzed human placental samples from different gestational ages and from women affected by inflammation-associated pregnancies.
RESULTS
Our data showed that repeated exposure of the human placenta to endotoxin challenges induced a tolerant phenotype characterized by decreased tumor necrosis factor alpha and up-regulated interleukin-10 levels. This reaction was mediated by the placenta-specific microRNA-519c packaged within placental extracellular vesicles. Lipopolysaccharide treatment increased the extracellular vesicles that were positive for the exosome tetraspanin markers, namely CD9, CD63, and CD81, and secreted primarily by trophoblasts. Primary human trophoblast cells transfected with a microRNA-519c mimic decreased phosphodiesterase 3B, whereas a lack of phosphodiesterase 3B, achieved by small interfering RNA transfection, led to decreased tumor necrosis factor alpha production. These data support the hypothesis that the anti-inflammatory action of microRNA-519c was mediated by a down-regulation of the phosphodiesterase 3B pathway, leading to inhibition of tumor necrosis factor alpha production. Furthermore, human placentas from normal and inflammation-associated pregnancies demonstrated that a decreased placental microRNA-519c level was linked to infection-induced inflammatory pathologies during pregnancy.
CONCLUSION
We identified microRNA-519c, a human placenta-specific microRNA, as a novel regulator of immune adaptation associated with infection-induced preterm birth at the maternal-fetal interface. Our study serves as a basis for future experiments to explore the potential use of microRNA-519c as a biomarker for infection-induced preterm birth.
Identifiants
pubmed: 34181894
pii: S0002-9378(21)00742-0
doi: 10.1016/j.ajog.2021.06.075
pmc: PMC8633060
mid: NIHMS1720628
pii:
doi:
Substances chimiques
Lipopolysaccharides
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
681.e1-681.e20Subventions
Organisme : NICHD NIH HHS
ID : R01 HD098258
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
BMC Genomics. 2007 Jun 12;8:166
pubmed: 17565689
Am J Obstet Gynecol. 1992 May;166(5):1515-28
pubmed: 1595807
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Am J Obstet Gynecol. 1992 May;166(5):1576-87
pubmed: 1595815
Front Immunol. 2018 Nov 20;9:2705
pubmed: 30515175
J Clin Epigenet. 2016;2(1):
pubmed: 27099870
Am J Obstet Gynecol. 1989 Aug;161(2):336-41
pubmed: 2764054
Life Sci. 2017 Apr 15;175:47-51
pubmed: 28315691
Cell. 2019 Apr 4;177(2):225-227
pubmed: 30951665
Reprod Sci. 2013 Feb;20(2):154-67
pubmed: 22614625
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000262
pubmed: 17253447
Sci Rep. 2020 Feb 20;10(1):3029
pubmed: 32080251
PLoS One. 2017 Feb 9;12(2):e0171756
pubmed: 28182660
Am J Reprod Immunol. 2019 Feb;81(2):e13080
pubmed: 30586203
Nucleic Acids Res. 2014 Jan;42(Database issue):D68-73
pubmed: 24275495
Reprod Sci. 2017 Oct;24(10):1382-1401
pubmed: 28122480
Clin Chem. 2008 Mar;54(3):482-90
pubmed: 18218722
J Reprod Immunol. 2013 Mar;97(1):51-61
pubmed: 23432872
Am J Obstet Gynecol. 2004 Oct;191(4):1339-45
pubmed: 15507963
Science. 2014 Aug 15;345(6198):760-5
pubmed: 25124429
FASEB J. 2017 Jul;31(7):2760-2770
pubmed: 28289056
BJOG. 2011 Jan;118(2):145-53
pubmed: 21054766
Reprod Biol Endocrinol. 2003 Dec 02;1:121
pubmed: 14651750
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11
pubmed: 14681370
Am J Obstet Gynecol. 2009 Jan;200(1):104.e1-11
pubmed: 19121663
PLoS One. 2013;8(3):e58502
pubmed: 23516492
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15144-9
pubmed: 17848513
Crit Care. 2013 Nov 14;17(6):242
pubmed: 24229432
J Immunol. 2009 May 15;182(10):6494-507
pubmed: 19414804
Am J Reprod Immunol. 2010 Mar 1;63(3):200-8
pubmed: 20055792
Am J Obstet Gynecol. 2015 Oct;213(4 Suppl):S29-52
pubmed: 26428501
Am J Obstet Gynecol. 1980 Jun 15;137(4):451-8
pubmed: 7386529
Shock. 2009 Jul;32(1):40-8
pubmed: 19106809
Curr Pharm Biotechnol. 2011 May;12(5):814-23
pubmed: 21342117
J Extracell Vesicles. 2015 Mar 26;4:26373
pubmed: 25819213
J Immunol. 2006 Oct 1;177(7):4888-96
pubmed: 16982931
Semin Reprod Med. 2007 Jan;25(1):21-39
pubmed: 17205421
Sci Rep. 2016 Nov 17;6:37246
pubmed: 27853258
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
pubmed: 21647195
Am J Reprod Immunol. 2011 Oct;66(4):259-69
pubmed: 21410811
J Immunol. 2000 Jun 1;164(11):5721-8
pubmed: 10820249
Inflamm Res. 2011 Sep;60(9):841-9
pubmed: 21556916
J Perinat Med. 2010;38(1):39-44
pubmed: 19708825
Biol Reprod. 2009 Oct;81(4):717-29
pubmed: 19494253
Am J Reprod Immunol. 2011 Oct;66(4):279-85
pubmed: 21481060
Am J Obstet Gynecol. 1994 Jul;171(1):158-64
pubmed: 8030692
Am J Reprod Immunol. 2008 Dec;60(6):482-96
pubmed: 19032609
Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8
pubmed: 17991681
Am J Obstet Gynecol. 2001 Nov;185(5):1137-42
pubmed: 11717647
Anesthesiology. 2000 Dec;93(6):1446-55
pubmed: 11149440
Am J Reprod Immunol. 2015 May;73(5):383-9
pubmed: 25244611
Diabetes. 2002 Oct;51(10):2929-35
pubmed: 12351429
Immunol Rev. 2013 May;253(1):112-28
pubmed: 23550642
Lancet. 2010 Apr 24;375(9724):1482-90
pubmed: 20223514
Endocrinology. 1986 Apr;118(4):1567-82
pubmed: 3512258
J Reprod Immunol. 2013 Mar;97(1):36-42
pubmed: 23432870
Innate Immun. 2014 Feb;20(2):214-24
pubmed: 23751819
Placenta. 2014 Apr;35(4):241-8
pubmed: 24581729
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7069-E7076
pubmed: 27791094
N Engl J Med. 2014 Jun 5;370(23):2211-8
pubmed: 24897084
Nucleic Acids Res. 2009 Jun;37(10):3464-73
pubmed: 19339516
Am J Reprod Immunol. 2009 Dec;62(6):390-9
pubmed: 19821803
Am J Reprod Immunol. 2010 Jul 1;64(1):38-57
pubmed: 20331587
Obstet Gynecol. 1993 Jun;81(6):941-8
pubmed: 8497360
Nanomedicine. 2011 Dec;7(6):780-8
pubmed: 21601655
Am J Reprod Immunol. 2014 Aug;72(2):141-7
pubmed: 24809430
Am J Obstet Gynecol. 2007 Sep;197(3):294.e1-6
pubmed: 17826426
Placenta. 2012 Sep;33(9):725-34
pubmed: 22721760
Am J Obstet Gynecol. 2014 Mar;210(3):221.e1-11
pubmed: 24565431
Cell Mol Immunol. 2014 Nov;11(6):571-81
pubmed: 24954221
Placenta. 2017 Oct;58:60-66
pubmed: 28962697
J Reprod Immunol. 1997 Jun;33(2):147-56
pubmed: 9234213
Am J Obstet Gynecol. 2001 Nov;185(5):1130-6
pubmed: 11717646
Am J Obstet Gynecol. 2009 Mar;200(3):308.e1-9
pubmed: 19114277
Am J Reprod Immunol. 2017 Mar;77(3):
pubmed: 28044385
Sci Rep. 2016 Jun 20;6:28056
pubmed: 27321128
Am J Obstet Gynecol. 2018 Mar;218(3):294-314.e2
pubmed: 29248470
Am J Reprod Immunol. 2014 Nov;72(5):458-74
pubmed: 25078709
Placenta. 2017 May;53:23-29
pubmed: 28487016
Arch Med Sci. 2015 Mar 16;11(1):67-77
pubmed: 25861291
Clin Exp Immunol. 2012 Apr;168(1):153-63
pubmed: 22385250
Semin Perinatol. 2001 Aug;25(4):204-14
pubmed: 11561908
Transplant Proc. 2011 Sep;43(7):2531-5
pubmed: 21911118
Nutr Rev. 2007 Dec;65(12 Pt 2):S194-202
pubmed: 18240548
Inflammation. 2014 Feb;37(1):268-76
pubmed: 24132662
Clin Chem. 2010 Nov;56(11):1767-71
pubmed: 20729298
Am J Obstet Gynecol. 1984 Mar 15;148(6):739-43
pubmed: 6702942
J Extracell Vesicles. 2018 Jan 21;7(1):1422674
pubmed: 29410778
Toxicology. 2007 May 20;234(3):167-75
pubmed: 17442477
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3536-E3545
pubmed: 28396435
Am J Obstet Gynecol. 2017 Jun;216(6):604.e1-604.e11
pubmed: 28257964
Shock. 2008 Sep;30(3):267-73
pubmed: 18197145
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4
pubmed: 16381832
Front Cardiovasc Med. 2017 Nov 03;4:68
pubmed: 29164135
Immunol Cell Biol. 2018 Mar 31;:
pubmed: 29604098
J Matern Fetal Neonatal Med. 2015 Aug;28(12):1394-409
pubmed: 25190175
DNA Cell Biol. 2015 Jun;34(6):437-57
pubmed: 25825993
Am J Reprod Immunol. 2006 Jan;55(1):19-27
pubmed: 16364008
Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7
pubmed: 21037258
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6
pubmed: 16885212
Clin Perinatol. 2011 Sep;38(3):385-406
pubmed: 21890015
Cell Mol Immunol. 2014 Nov;11(6):538-47
pubmed: 24954225
Mol Hum Reprod. 2012 Aug;18(8):417-24
pubmed: 22383544
Semin Fetal Neonatal Med. 2006 Oct;11(5):317-26
pubmed: 16839830
Immunol Today. 1993 Jul;14(7):353-6
pubmed: 8363725
Placenta. 2014 Feb;35 Suppl:S69-73
pubmed: 24280233